{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:13:07Z","timestamp":1772165587011,"version":"3.50.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,1,9]],"date-time":"2023-01-09T00:00:00Z","timestamp":1673222400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,9]],"date-time":"2023-01-09T00:00:00Z","timestamp":1673222400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Potent P2Y\n                      <jats:sub>12<\/jats:sub>\n                      inhibitors are recommended for up to 12\u00a0months after percutaneous coronary intervention (PCI) in patients diagnosed with acute coronary syndrome (ACS). However, the prescription pattern is diverse in real world practice, which includes various switching between antiplatelet regimens. In this study, we analyzed the prescription patterns of prasugrel, and assessed the safety and effectiveness of P2Y12 inhibitors switching patterns in a real world registry of patients subjected to PCI after ACS.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The EFF-K study included 3077 ACS patients receiving prasugrel-based dual antiplatelet therapy. The cohort was divided into those who were administered with prasugrel as the primary antiplatelet treatment (na\u00efve cohort) or as a substitute agent after clopidogrel or ticagrelor pre-treatment (switch cohort). The primary endpoint was a net adverse clinical event (NACE; a composite of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, or TIMI major bleeding unrelated to coronary-artery bypass grafting).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 3077 patients diagnosed with ACS were included in the analysis. Among the total population, 726 patients (23.6%) were classed as the na\u00efve cohort and 2351 patients (76.4%) as the switch cohort. Baseline characteristics showed that the switch cohort had more comorbidities, such as hypertension, diabetes mellitus, heart failure and previous PCI. The major cause of switching to prasugrel in the switch cohort was the necessity for a more potent antiplatelet agent (56.3%). During a 12-month follow-up period, 51 patients (1.7%) experienced at least one NACE. The incidence of NACE did not differ between the na\u00efve and switch cohort (1.5% vs. 1.7%, Hazard ratio 1.17, 95% Confidence interval 0.56\u20132.43,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.677). In subgroup analysis, no significant interaction was observed between the treatment strategy and the incidence of NACE across various subgroups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Dual antiplatelet therapy with prasugrel seems to be safe and effective both as a primary treatment and as a substitute for other P2Y12 inhibitors in a real world registry of Asian ACS patients receiving PCI.<\/jats:p>\n                    <jats:p>\n                      <jats:italic>Trial registration<\/jats:italic>\n                      : KCT0002356, registered June 13, 2017.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12872-022-03034-5","type":"journal-article","created":{"date-parts":[[2023,1,9]],"date-time":"2023-01-09T00:05:57Z","timestamp":1673222757000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Real-world evidence of switching P2Y12 receptor\u2013inhibiting therapies to prasugrel after PCI in patients with ACS: results from EFF-K registry"],"prefix":"10.1186","volume":"23","author":[{"given":"Jeehoon","family":"Kang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jung-Kyu","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Han-Mo","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyung Woo","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyun-Jae","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bon-Kwon","family":"Koo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eun Ho","family":"Choo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jong-Young","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang-Don","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young-Hyo","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyung-Min","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji-Hyun","family":"Heo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyo-Soo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,1,9]]},"reference":[{"key":"3034_CR1","doi-asserted-by":"publisher","first-page":"256","DOI":"10.21037\/atm.2016.06.33","volume":"4","author":"F Sanchis-Gomar","year":"2016","unstructured":"Sanchis-Gomar F, Perez-Quilis C, Leischik R, et al. Epidemiology of coronary heart disease and acute coronary syndrome. Ann Transl Med. 2016;4:256. https:\/\/doi.org\/10.21037\/atm.2016.06.33.","journal-title":"Ann Transl Med"},{"key":"3034_CR2","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1001\/jama.2018.5281","volume":"319","author":"DL Bhatt","year":"2018","unstructured":"Bhatt DL. Percutaneous coronary intervention in 2018. JAMA. 2018;319:2127\u20138.","journal-title":"JAMA"},{"key":"3034_CR3","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.ijcard.2012.01.080","volume":"167","author":"F D'Ascenzo","year":"2013","unstructured":"D\u2019Ascenzo F, Bollati M, Clementi F, et al. Incidence and predictors of coronary stent thrombosis: evidence from an international collaborative meta-analysis including 30 studies, 221,066 patients, and 4276 thromboses. Int J Cardiol. 2013;167:575\u201384.","journal-title":"Int J Cardiol"},{"key":"3034_CR4","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1093\/eurheartj\/ehaa575","volume":"42","author":"J-P Collet","year":"2020","unstructured":"Collet J-P, Thiele H, Barbato E, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2020;42:1289\u2013367. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa575.","journal-title":"Eur Heart J"},{"key":"3034_CR5","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","volume":"357","author":"SD Wiviott","year":"2007","unstructured":"Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357:2001\u201315.","journal-title":"N Engl J Med"},{"key":"3034_CR6","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1161\/CIRCULATIONAHA.117.031164","volume":"136","author":"DJ Angiolillo","year":"2017","unstructured":"Angiolillo DJ, Rollini F, Storey RF, et al. International expert consensus on switching platelet P2Y(12) receptor-inhibiting therapies. Circulation. 2017;136:1955\u201375.","journal-title":"Circulation"},{"key":"3034_CR7","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/nrcardio.2014.104","volume":"11","author":"GN Levine","year":"2014","unstructured":"Levine GN, Jeong Y-H, Goto S, et al. Expert consensus document: World Heart Federation expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI. Nat Rev Cardiol. 2014;11:597\u2013606.","journal-title":"Nat Rev Cardiol"},{"key":"3034_CR8","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.scib.2018.12.020","volume":"64","author":"Y Huo","year":"2019","unstructured":"Huo Y, Jeong Y-H, Gong Y, et al. 2018 update of expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI. Sci Bull. 2019;64:166\u201379.","journal-title":"Sci Bull"},{"key":"3034_CR9","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1055\/s-0038-1626697","volume":"118","author":"J Kang","year":"2018","unstructured":"Kang J, Han J-K, Ahn Y, et al. Third-generation P2Y12 inhibitors in East Asian acute myocardial infarction patients: a nationwide prospective multicentre study. Thromb Haemost. 2018;118:591\u2013600.","journal-title":"Thromb Haemost"},{"key":"3034_CR10","doi-asserted-by":"publisher","first-page":"537","DOI":"10.4070\/kcj.2018.0166","volume":"48","author":"J Kang","year":"2018","unstructured":"Kang J, Kim HS. The evolving concept of dual antiplatelet therapy after percutaneous coronary intervention: focus on unique feature of East Asian and \u201cAsian Paradox.\u201d Korean Circ J. 2018;48:537\u201351.","journal-title":"Korean Circ J"},{"key":"3034_CR11","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1055\/s-0038-1676545","volume":"119","author":"J Kang","year":"2019","unstructured":"Kang J, Park KW, Palmerini T, et al. Racial differences in ischaemia\/bleeding risk trade-off during anti-platelet therapy: individual patient level landmark meta-analysis from seven RCTs. Thromb Haemost. 2019;119:149\u201362.","journal-title":"Thromb Haemost"},{"key":"3034_CR12","doi-asserted-by":"publisher","first-page":"2632","DOI":"10.1093\/eurheartj\/ehz372","volume":"40","author":"P Urban","year":"2019","unstructured":"Urban P, Mehran R, Colleran R, et al. Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk. Eur Heart J. 2019;40:2632\u201353.","journal-title":"Eur Heart J"},{"key":"3034_CR13","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1161\/CIRCULATIONAHA.119.041766","volume":"140","author":"D-W Park","year":"2019","unstructured":"Park D-W, Kwon O, Jang J-S, et al. Clinically significant bleeding with ticagrelor versus clopidogrel in Korean patients with acute coronary syndromes intended for invasive management: a randomized clinical trial. Circulation. 2019;140:1865\u201377.","journal-title":"Circulation"},{"key":"3034_CR14","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1253\/circj.CJ-20-0125","volume":"84","author":"M-K Chon","year":"2020","unstructured":"Chon M-K, Jung S-M, Lee S-Y, et al. Incidence of cardiovascular events and safety profile of prasugrel in Korean patients with acute coronary syndrome. Circ J. 2020;84:1582\u20136.","journal-title":"Circ J"},{"key":"3034_CR15","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1016\/j.amjcard.2017.07.013","volume":"120","author":"MC Alraies","year":"2017","unstructured":"Alraies MC, Lee SY, Lipinski MJ, et al. Effect of bleeding risk on type of stent used in patients presenting with acute coronary syndrome. Am J Cardiol. 2017;120:1272\u20138.","journal-title":"Am J Cardiol"},{"key":"3034_CR16","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrcardio.2015.113","volume":"13","author":"F Rollini","year":"2016","unstructured":"Rollini F, Franchi F, Angiolillo DJ. Switching P2Y12-receptor inhibitors in patients with coronary artery disease. Nat Rev Cardiol. 2016;13:11\u201327.","journal-title":"Nat Rev Cardiol"},{"key":"3034_CR17","first-page":"67","volume":"6","author":"F Rollini","year":"2017","unstructured":"Rollini F, Franchi F, Angiolillo DJ. Switching P2Y(12) receptor inhibiting therapies. Interv Cardiol Clin. 2017;6:67\u201389.","journal-title":"Interv Cardiol Clin"},{"key":"3034_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.vph.2019.01.003","volume":"115","author":"A Gasecka","year":"2019","unstructured":"Gasecka A, Konwerski M, Pordzik J, et al. Switching between P2Y(12) antagonists\u2014from bench to bedside. Vascul Pharmacol. 2019;115:1\u201312.","journal-title":"Vascul Pharmacol"},{"key":"3034_CR19","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.vph.2019.03.001","volume":"116","author":"P Capranzano","year":"2019","unstructured":"Capranzano P, Capodanno D. Switching between P2Y(12) inhibitors: rationale, methods, and expected consequences. Vascul Pharmacol. 2019;116:4\u20137.","journal-title":"Vascul Pharmacol"},{"key":"3034_CR20","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s11886-014-0485-4","volume":"16","author":"Y-H Jeong","year":"2014","unstructured":"Jeong Y-H. \u201cEast Asian paradox\u201d: challenge for the current antiplatelet strategy of \u201cone-guideline-fits-all races\u201d in acute coronary syndrome. Curr Cardiol Rep. 2014;16:485. https:\/\/doi.org\/10.1007\/s11886-014-0485-4.","journal-title":"Curr Cardiol Rep"},{"key":"3034_CR21","doi-asserted-by":"publisher","first-page":"888","DOI":"10.4070\/kcj.2017.0072","volume":"47","author":"C Kim","year":"2017","unstructured":"Kim C, Shin DH, Ahn CM, et al. The use pattern and clinical impact of new antiplatelet agents including prasugrel and ticagrelor on 30-day outcomes after acute myocardial infarction in Korea: Korean health insurance review and assessment data. Korean Circ J. 2017;47:888\u201397.","journal-title":"Korean Circ J"},{"key":"3034_CR22","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1016\/j.ahj.2015.03.015","volume":"169","author":"H-J Kang","year":"2015","unstructured":"Kang H-J, Clare RM, Gao R, et al. Ticagrelor versus clopidogrel in Asian patients with acute coronary syndrome: a retrospective analysis from the Platelet Inhibition and Patient Outcomes (PLATO) trial. Am Heart J. 2015;169:899\u2013905.","journal-title":"Am Heart J"},{"key":"3034_CR23","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1253\/circj.CJ-13-1482","volume":"78","author":"S Saito","year":"2014","unstructured":"Saito S, Isshiki T, Kimura T, et al. Efficacy and safety of adjusted-dose prasugrel compared with clopidogrel in Japanese patients with acute coronary syndrome: the PRASFIT-ACS study. Circ J. 2014;78:1684\u201392.","journal-title":"Circ J"},{"key":"3034_CR24","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.1253\/circj.CJ-15-0112","volume":"79","author":"S Goto","year":"2015","unstructured":"Goto S, Huang C-H, Park S-J, et al. Ticagrelor vs. clopidogrel in Japanese, Korean and Taiwanese patients with acute coronary syndrome\u2014randomized, double-blind, phase III PHILO study. Circ J. 2015;79:2452\u201360.","journal-title":"Circ J"},{"issue":"4","key":"3034_CR25","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.jacc.2020.11.046","volume":"77","author":"S Leonardi","year":"2021","unstructured":"Leonardi S, Gragnano F, Carrara G, et al. Prognostic implications of declining hemoglobin content in patients hospitalized with acute coronary syndromes. J Am Coll Cardiol. 2021;77(4):375\u201388.","journal-title":"J Am Coll Cardiol"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-022-03034-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12872-022-03034-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-022-03034-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,12]],"date-time":"2023-01-12T04:03:04Z","timestamp":1673496184000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccardiovascdisord.biomedcentral.com\/articles\/10.1186\/s12872-022-03034-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,9]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["3034"],"URL":"https:\/\/doi.org\/10.1186\/s12872-022-03034-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-1651511\/v1","asserted-by":"object"}]},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,9]]},"assertion":[{"value":"13 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The protocol of this study was approved by the Institutional Review Board at Seoul National University Hospital (H-1702-054-832) and the ethics committee of each participating institutions. Written informed consent was obtained for all patients registered in the study. The study was conducted in accordance with the principles established by the Declaration of Helsinki (2013).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"H-SK has received research grants or speaker\u2019s fees from Daiichi Sankyo, Medtronic, Abbott Vascular, Edwards Life Science, Boston Scientific, Terumo, Biotronik and Dio, Amgen, Pfizer, AstraZeneca, MSD and Behringer Ingelheim. H-MK and J-HH are full-time employees of Daiichi Sankyo Korea. All other authors (JK, J-KH, H-MY, KWP, H-JK, B-KK, E-HC, J-YL, S-DP, and Y-HL) have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6"}}